Individualized prediction of treatment effects using data from both embedded clinical trials and electronic health records

Ended Project Grant Awarded Last action

Award ID
R01HL164835
Recipient
Awarding agency
Obligated
$2,405,054

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date
Originally
Place of performance
Pennsylvania, USA

Award details come from USAspending.gov.

Description

Abstract
More than 790,000 patients undergo mechanical ventilation for acute respiratory failure (ARF) in the united states each year at a cost of $27 billion. The in-hospital mortality for these patients is nearly 35%, and for patients with critical illness, such as acute respiratory distress syndrome (ards), mortality can approach 50%. In some patients, guideline-appropriate care with lung-protective ventilation or prone positioning will save lives, yet in many others, an individualized treatment is elusive. There is a need for advances in leveraging opportunities in data science to improve outcomes from respiratory failure. The primary method for generating new evidence is the randomized clinical trial (RCT). Yet they are often costly, take many years, and can be slow to accelerate learning and implementation at the bedside. In addition, rcts usually enroll a moderate number of patients at high cost (100 to 1000S) and measure a limited range of covariates (10 to 100S). Thus, they do not lead to prediction of highly individualized treatment effects, as called for by the nhlbi working group on research priorities. In contrast, real-world evidence from electronic health records (ehrs) includes many patients (often millions) and covariates (often 1000S). They are inherently generalizable, less costly, and less timely to acquire than conducting rcts. However, the estimation of treatment effects from EHR data is often biased due to confounding, which occurs when a treatment and its effect(s) are both causally influenced by one or more events. This project uses two specific aims to solve these challenges. Aim 1 proposes to develop and evaluate a new method for making individualized predictions of treatment effects using data from rcts and ehrs. IT uses "embedded" rcts in which the clinical trial occurs within the context of usual care of a health system. The embedded RCT data are applied to control for confounding when using EHR data to predict treatment effects. Aim 2 will apply these methods to two embedded rcts at upmc that are studying treatments that may help prevent ARF. The optimise c-19 trial is studying monoclonal antibody therapy for non-hospitalized patients with sars-COV-2 infection. The periop trial will be studying perioperative interventions to improve post-operative outcomes after major surgery. The hypothesis to be investigated is that the proposed new methods will predict the effects of treatment on acute respiratory failure and other outcomes more accurately than will using the clinical trial or the EHR data alone. Such results would provide support that these methods yield individualized predictions of treatment effects that can inform clinical care to help prevent ARF.

Transactions

Action Obligated Date
Amendment $0
Amendment $575,480
Amendment $603,080
Amendment $0
Amendment $613,247
Original award $613,247

Subawards

Subrecipient Amount Awarded
University Of Crete Individualized Prediction of Treatment Effects Using Data from Both Embedded Clinical Trials and Electronic Health Records $41,102
University Of Crete $41,102

Quick answers

Who received award R01HL164835?

R01HL164835 was awarded to University Of Pittsburgh - Of The Commonwealth System Of Higher Education by National Heart Lung and Blood Institute (National Institutes of Health) on September 15, 2022.

How much is award R01HL164835 worth?

$2,405,054 has been obligated on R01HL164835.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award